Kajalakshmy M. “Phase Ii Trial Of Bevacizumab, Irinotecan, And Cetuximab In Recurrent Glioblastoma Multiforme: Efficacy, Safety And Clinical Outcomes”. Journal for ReAttach Therapy and Developmental Diversities 5, no. 2 (December 20, 2022): 788–792. Accessed February 11, 2026. https://jrtdd.com/index.php/journal/article/view/3854.